Compare BCAL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | DRUG |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 778.4M |
| IPO Year | 2020 | 2020 |
| Metric | BCAL | DRUG |
|---|---|---|
| Price | $21.29 | $78.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $20.67 | ★ $129.25 |
| AVG Volume (30 Days) | 168.0K | ★ 176.6K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 777.27 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | $24.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.87 | $38.00 |
| 52 Week High | $22.00 | $123.75 |
| Indicator | BCAL | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 51.33 |
| Support Level | $20.36 | $76.54 |
| Resistance Level | $21.80 | $83.65 |
| Average True Range (ATR) | 0.39 | 3.76 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 50.42 | 29.69 |
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.